Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

chromophobe renal cell carcinoma - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

chromophobe renal cell carcinoma

MONDO:0017885

Also known as:chromophobe adenocarcinomachromophobe carcinomachromophobe carcinoma of kidney

Find Clinical TrialsTrials

Overview

Chromophobe renal cell carcinoma is a rare subtype of renal cell carcinoma, originating from the intercalating cells of the collecting ducts and macroscopically manifesting as a well-circumscribed, highly lobulated, solid tumor that is usually diagnosed at an early stage. It is frequently asymptomatic, or may present with nonspecific symptoms, such as weight loss, fever or fatigue. The classic presentation observed in renal tumors (hematuria, flank pain and palpable mass) is occasionally observed and usually indicates an advanced stage of the disease. It is most frequently sporadic however, several familial cases, associated with Birt-Hogg DubC) syndrome, have been described.

Clinical Trials10 registered · 3 recruiting

Diagnosis

Biomarker and diagnostic research for chromophobe renal cell carcinoma has been reported in the published literature.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

10 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 5 PHASE2, 1 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT04623502](https://clinicaltrials.gov/study/NCT04623502)

Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 1:52 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:319303

GARD

Genetic and Rare Diseases Info Center

GARD:6064

Questions for Your Care Team

→Are any of the 10 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	59	26%
Laboratory research	50	22%
Patient case studies	49	22%
Testing and diagnosis research	32	14%
Disease patterns and progression	21	9%
Clinical study results	6	3%
New treatment approaches	4	2%
Other research	3	1%

chromophobe renal cell carcinoma

Overview

Diagnosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications